Tuesday, October 27, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Data Presentation On Quality of Life and Symptoms. Eledon presented data from the Phase 2 BESTOW trial at the American Society of Nephrology Annual Kidney Week 2026 meeting. The presentation compared patients receiving tegoprubart with those receiving tacrolimus, showing improvements in quality of life and reductions in symptom burden at 12 months. We believe these findings support prior data on efficacy, safety, and tolerability.
Patient Evaluations. Data from two accepted clinical evaluations, MTSOSD-59R and KDQOL-SF, showed substantial, lasting improvements in quality of life and reductions in transplant-related side effects. We see these patient-reported outcomes as consistent with prior reductions in BPAR (Biopsy-Proven Acute Rejection), improvements in eGFR, and improvements in factors that contribute to long-term graft failure.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.